BOCA RATON, Fla., May 22 /PRNewswire-FirstCall/ -- Dawson James
Securities, a full-service investment firm serving the healthcare and
biotechnology industry, reiterated their Speculative Buy recommendation on
Biopure Corp. (Nasdaq: BPUR) with a 12-18 month price target of $3.00.
Stephen M. Dunn, Director of Research, issued the report.
The update report describes Biopure's Hemopure(R), a hemoglobin-based
oxygen carrier, and the anticipated U.S. Navy IND submission to the FDA to
begin the RESUS Phase II clinical trial for out-of-hospital trauma and the
company's pending marketing authorization submission in the U.K. The report
also highlights the significant differences between Hemopure(R) and
competitor Northfield Laboratories (Nasdaq: NFLD) Polyheme(R).
Additionally, the report describes the multiple ongoing European
clinical trials for Hemopure(R) such as the 60-patient Phase II trial in
coronary artery bypass graft (CABG) surgery, the 100-patient Phase II trial
in vascular disease lower limb amputation and the Phase II trial in the
Netherlands in percutaneous coronary intervention (PCI), all of which are
Finally, the report describes the emerging FDA safety concerns for
erythropoiesis stimulating agents (ESAs) in chemotherapy-induced anemia
patients such as Amgen's (NASDAQ: AMGN) Aranesp(R) and Epogen(R) as well as
Johnson & Johnson's (NYSE: JNJ) Procrit(R). Mr. Dunn states "The negative
issues surrounding ESAs may eventually provide a new and significant future
indication for Biopure's Hemopure(R) in treating chemotherapy-induced
anemia patients." He notes that total sales of ESAs in 2006, for all
indications, were over $10 billion.
A copy of the report may be obtained by contacting Dawson James
Securities at 561-391-5555.
About Dawson James Securities:
Dawson James Securities is a full service investment firm with deep
expertise in healthcare and biotechnology and having a staff of over 50
investment professionals providing institutional research, investment
banking and high net worth services to our clients. More information is
available at www.DawsonJames.com
Dawson James has acted as an investment banker for Biopure Corp. and
the Firm and/or its directors and employees may own securities in the
companies and may increase or decrease holdings in the future.
The analyst certifies that 1) all of the views expressed accurately
reflect his personal views about any and all of the subject securities or
issuers discussed; and 2) no part of the research analyst's compensation
was, is, or will be directly or indirectly related to the specific
recommendations or views expressed by the research analyst; 3) the analyst
responsible for preparing this research report receives compensation based
upon various factors, including total revenues of Dawson James and its
affiliates, a portion of which is generated by investment banking
activities and 4) the analyst and/or members of their immediate family do
not own stock in the companies mentioned.
Dawson James Securities
Stephen M. Dunn, 561-208-2905
Dawson James Securities is a member of the National Association of
Securities Dealers, CRD number 130645.
SOURCE Dawson James Securities